Answers are grounded in this paper and cite their sources.
Abstract Background Surgical debulking for metastatic gastroenteropancreatic neuroendocrine tumors (GEP-NETs) is associated with increased progression-free survival (PFS) and overall survival (OS) in retrospective studies. It remains unclear, however, which patients benefit most from surgery. DOTATATE PET/CT tumor volume (TV) in metastatic GEP-NETs has been shown to correlate with PFS and OS. Herein, we investigate how TV impacts outcomes in patients undergoing surgical debulking for GEP-NETs. Methods A retrospective chart review was conducted of patients with pancreatic and small bowel NET (PNET/SBNET) who underwent surgical debulking at our institution from 2019 to 2022. All patients had an estimated liver debulking threshold of > 90 % and only patients with preoperative ⁶⁸Ga or ⁶⁴Cu-DOTATATE PET/CT were included. TV was obtained using the MIM Encore workstation. Results 71 patients with metastatic GEP-NETs (35 % PNET and 65 % SBNET) underwent liver debulking with 19 synchronous primary tumor resections. 42 patients had symptomatic disease. Patients were divided into 4 TV quartiles, ranging from 8.46 to 2000 mL. On cox proportional hazards modeling, tumor volume stratified by quartiles was not significantly associated with longer PFS (p = 0.250) over a median follow-up of 13 months (7−23). However, there was an increased risk for Clavien-Dindo Grade III and IV complications with higher TV quartiles (p = 0.008). SBNETs with carcinoid syndrome (p = 0.047) and those with more lesions debulked (p = 0.025) were more likely to have improvement in postoperative symptoms. Conclusion Patients with larger tumor burden on preoperative DOTATATE PET/CT should not be excluded from surgical intervention but may need to be counseled on higher risks of operative complications.
No takes yet. Share an insight, caveat, or question.
Azar et al. (2025) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: